• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: West’s device aids in dose-sparing administration of polio vaccine

October 10, 2017 By Sarah Faulkner

WestWest Pharmaceutical Services (NYSE:WST) touted results today from a study showing that its ID Adapter can improve the intradermal administration of polio vaccines.

The study, published in the journal Vaccine, evaluated the feasibility of using a fractional inactivated polio virus vaccine in remote locations where polio outbreaks continue to be of serious concern to public health officials.

Previous work has shown that a 20% fractional dose of intradermal IPV is just as effective as a full dose of intramuscular IPV. West’s ID Adapter helps to guide the angle and limit the depth of needle insertion in intradermal administration of a drug, the company said.

In this study, West’s ID Adapter was used with a staked needle syringe from Helm Medical Gmbh.

“We are pleased that our ID Adapter performed so well in this critical research study that addresses a vital medical need,” Karen Flynn, West’s SVP & CCO, said in prepared remarks. “West is proud to offer a solution that can help improve the reliability and performance of intradermal injections while also extending the limited supply of IPV.”

The study, which was conducted in Pakistan, compared the usability and immune response of intradermal fractional IPV administration in kids ages 6-12 months with two novel intradermal adapters – one of which was developed by West.

In the second part of the study, the researchers assessed the feasibility of a door-to-door vaccination campaign to give the intradermal IPV to kids under five years old.

The team found that the immune response achieved with one dose of IPV administered using Helm’s syringe and West’s ID Adapter was similar to the response achieved by a fractional IPV administered with a needle and syringe.

The researchers also reported that intradermal IPV can be used for primary immunization and as an alternative to full-dose IPV.

See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: West Pharmaceutical Services

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS